Tag #Glp-1

Showing 1 to 12 of 31 results

theguardian.com

🌐 85% Global Worthiness

Sep 20, 10:17

GLP-1 Agonists: Mechanisms of Weight Loss and Altered Taste Perception

New studies reveal that GLP-1 receptor agonists, like semaglutide and tirzepatide, induce weight loss in people with obesity by reducing appetite, slowing gastric emptying, increasing satiety, and altering taste perception, leading to reduced consumption of unhealthy foods.

GLP-1 Agonists: Mechanisms of Weight Loss and Altered Taste Perception

New studies reveal that GLP-1 receptor agonists, like semaglutide and tirzepatide, induce weight loss in people with obesity by reducing appetite, slowing gastric emptying, increasing satiety, and altering taste perception, leading to reduced consumption of unhealthy foods.

Progress

20% Bias Score

ShareSaveArticle

Zero Hunger

12345678

Previous 1 of 8 Next

What are the reported effects of GLP-1 agonists on food preferences and taste?

Many patients report a decreased preference for fatty, sugary, and salty foods. A study found that about 20% of patients experienced food tasting saltier or sweeter, correlating with increased feelings of fullness and reduced appetite. This mirrors the effects seen after bariatric surgery where endogenous GLP-1 levels increase.

es.euronews.com

🌐 75% Global Worthiness

Sep 2, 10:17

Denmark's Economic Growth Forecast Halved Due to Novo Nordisk's Slowdown

Denmark's economic growth forecast for 2025 has been cut in half to 1.4 percent, primarily due to lower-than-expected sales of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, after a 3.7 percent growth in 2023 driven by pharmaceutical exports.

Denmark's Economic Growth Forecast Halved Due to Novo Nordisk's Slowdown

Denmark's economic growth forecast for 2025 has been cut in half to 1.4 percent, primarily due to lower-than-expected sales of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, after a 3.7 percent growth in 2023 driven by pharmaceutical exports.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary reason for Denmark's revised economic growth forecast?

The significant reduction in Denmark's economic growth forecast from 3 percent to 1.4 percent is primarily attributed to the underperformance of Novo Nordisk, the pharmaceutical giant responsible for the popular weight-loss drugs Ozempic and Wegovy. This is due to factors such as increased competition, inventory buildup, and reduced US exports in early 2025.

bbc.com

🌐 75% Global Worthiness

Aug 23, 19:18

Serena Williams's Weight-Loss Medication Admission Sparks Body Image Debate

Tennis star Serena Williams revealed her use of weight-loss medication to combat post-partum weight gain, sparking discussion about body image pressures on female athletes and the accessibility of such treatments.

Serena Williams's Weight-Loss Medication Admission Sparks Body Image Debate

Tennis star Serena Williams revealed her use of weight-loss medication to combat post-partum weight gain, sparking discussion about body image pressures on female athletes and the accessibility of such treatments.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate societal implications of Serena Williams's public admission of using weight-loss medication?

Serena Williams, a 43-year-old tennis star, publicly disclosed her use of weight-loss medication, aiming to destigmatize such treatments. She lost 30 pounds in eight months while also exercising and focusing on diet. This honesty might encourage others to seek similar help, but it also raises concerns about the pressure on women to maintain an ideal body image.

us.cnn.com

🌐 75% Global Worthiness

Aug 18, 22:16

GLP-1 Weight Loss Drugs: Significant Muscle Loss Risk

Over 15 million Americans use GLP-1 drugs for weight loss, but these medications can cause significant muscle loss (15-60% of weight lost), impacting strength and potentially leading to falls and functional decline, especially in older adults. To mitigate this, strength training and a high-protein d...

GLP-1 Weight Loss Drugs: Significant Muscle Loss Risk

Over 15 million Americans use GLP-1 drugs for weight loss, but these medications can cause significant muscle loss (15-60% of weight lost), impacting strength and potentially leading to falls and functional decline, especially in older adults. To mitigate this, strength training and a high-protein d...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the mechanism of GLP-1 drugs contribute to muscle loss, and what are the implications for different age groups?

The loss of muscle mass associated with GLP-1 drugs is due to the medications' appetite-suppressing effects, resulting in reduced nutrient intake and potentially inadequate fueling for workouts. This is particularly concerning for older adults already at risk of sarcopenia (age-related muscle loss).

us.cnn.com

🌐 85% Global Worthiness

Aug 7, 16:17

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Eli Lilly's orforglipron Phase 3 trial results on obesity treatment?

In a Phase 3 trial, Eli Lilly's orforglipron, a once-daily oral GLP-1 pill, facilitated a 12.4% average weight reduction in obese adults over 72 weeks. This involved 3,127 participants with at least one weight-related health issue, excluding diabetes. The highest dose resulted in 59.6% achieving 10% weight loss and 39.6% achieving 15% weight loss.

abcnews.go.com

🌐 75% Global Worthiness

Jul 24, 04:12

Weight Regain Follows GLP-1 Medication Discontinuation

A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.

Weight Regain Follows GLP-1 Medication Discontinuation

A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate effects of stopping GLP-1 weight-loss medications, and what does this imply about the long-term management of obesity?

A new study shows that people who discontinue GLP-1 medications like Wegovy and Ozempic for weight loss regain a significant portion of the lost weight within two months. The weight regain often continues for several months before stabilizing. This is consistent with other chronic disease treatments where the medication's effects cease upon discontinuation.

euronews.com

🌐 85% Global Worthiness

Sep 2, 10:17

Denmark's Economic Growth Forecast Cut in Half Amidst Novo Nordisk Slowdown

Denmark's 2025 economic growth forecast has been slashed from 3% to 1.4% due to weaker-than-expected performance by Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, resulting from increased competition, inventory buildup, and new US tariffs.

Denmark's Economic Growth Forecast Cut in Half Amidst Novo Nordisk Slowdown

Denmark's 2025 economic growth forecast has been slashed from 3% to 1.4% due to weaker-than-expected performance by Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, resulting from increased competition, inventory buildup, and new US tariffs.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary cause for Denmark's significantly reduced economic growth projection?

The sharp decrease in Denmark's economic growth forecast from 3% to 1.4% is primarily attributed to the underperformance of Novo Nordisk, a pharmaceutical giant whose weight-loss drugs, Ozempic and Wegovy, have seen decreased exports to the US due to increased competition and newly imposed tariffs. This slowdown in Novo Nordisk's performance significantly impacts Denmark's economy, which heavily relies on pharmaceutical exports.

bbc.com

🌐 85% Global Worthiness

Aug 23, 01:17

Serena Williams' Weight Loss: GLP-1 Medication, and the Destigmatization of Weight Management

Serena Williams, a 43-year-old retired tennis star, publicly revealed her use of GLP-1 weight-loss medication after struggling to lose weight postpartum despite rigorous training, aiming to destigmatize such treatments and advocate for a more comprehensive approach to weight management.

Serena Williams' Weight Loss: GLP-1 Medication, and the Destigmatization of Weight Management

Serena Williams, a 43-year-old retired tennis star, publicly revealed her use of GLP-1 weight-loss medication after struggling to lose weight postpartum despite rigorous training, aiming to destigmatize such treatments and advocate for a more comprehensive approach to weight management.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Williams's experience challenge prevailing societal views on weight loss and the use of medication?

Williams's openness aims to destigmatize weight-loss medication, countering the notion that such drugs represent an easy way out. Her experience resonates with many women struggling with postpartum weight, potentially normalizing medication use as part of a broader weight management strategy.

us.cnn.com

🌐 85% Global Worthiness

Aug 19, 04:15

Novo Nordisk Offers $499 Ozempic to US Patients

Novo Nordisk is offering a monthly supply of Ozempic for $499 to US patients who pay out-of-pocket, responding to President Trump's calls to lower drug costs and addressing sales impacts from compounding pharmacies.

Novo Nordisk Offers $499 Ozempic to US Patients

Novo Nordisk is offering a monthly supply of Ozempic for $499 to US patients who pay out-of-pocket, responding to President Trump's calls to lower drug costs and addressing sales impacts from compounding pharmacies.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Novo Nordisk's discounted Ozempic pricing on US patients and the pharmaceutical industry?

Novo Nordisk announced a $499 monthly price for Ozempic for cash-paying US patients, bypassing insurance. This follows President Trump's pressure on drugmakers to lower costs and comes after Novo Nordisk introduced a similar price for Wegovy.

abcnews.go.com

🌐 85% Global Worthiness

Aug 7, 16:18

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings from Eli Lilly's Phase 3 trial on the efficacy and safety of orforglipron in weight loss and cardiovascular health?

Eli Lilly announced that its new oral GLP-1 pill, orforglipron, resulted in an average weight loss of 27.3 pounds over 72 weeks in a Phase 3 trial involving over 3,100 overweight or obese adults. The highest dose (36mg) led to approximately 12% body weight reduction. This offers a potential non-injectable alternative to existing treatments.

foxnews.com

🌐 85% Global Worthiness

Aug 1, 22:18

GLP-1 Drugs Show Promise in Treating Rheumatoid Arthritis

GLP-1 medications, used for diabetes and weight loss, show promise in treating rheumatoid arthritis (RA) by potentially reducing inflammation; some patients saw relief and stopped using their RA medications, although more research is needed.

GLP-1 Drugs Show Promise in Treating Rheumatoid Arthritis

GLP-1 medications, used for diabetes and weight loss, show promise in treating rheumatoid arthritis (RA) by potentially reducing inflammation; some patients saw relief and stopped using their RA medications, although more research is needed.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the observed anti-inflammatory effects of GLP-1s potentially impact the treatment and management of rheumatoid arthritis?

The positive effects of GLP-1s extend beyond weight management; they are being investigated for their anti-inflammatory properties. A connection exists between obesity and RA, and GLP-1 medications may mitigate RA by impacting the body's inflammatory response. This is evidenced by patient reports of symptom relief and cessation of other RA medications.

dailymail.co.uk

🌐 85% Global Worthiness

Jul 23, 07:14

GLP-1 Drugs Show Promise in Reducing Dementia Risk for Type 2 Diabetes Patients

A study of 174,458 type 2 diabetes patients (2004-2024) found GLP-1 drugs reduced dementia risk by up to 25 percent compared to metformin, also lowering overall death rates; further research is needed.

GLP-1 Drugs Show Promise in Reducing Dementia Risk for Type 2 Diabetes Patients

A study of 174,458 type 2 diabetes patients (2004-2024) found GLP-1 drugs reduced dementia risk by up to 25 percent compared to metformin, also lowering overall death rates; further research is needed.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the mechanisms of action of GLP-1 receptor agonists and metformin differ, and how might these differences explain the observed variations in dementia risk reduction?

The study highlights GLP-1's potential as a first-line therapy for type 2 diabetes due to its direct effects on the central nervous system, unlike metformin. This contrasts with metformin's systemic metabolic effects, suggesting a more targeted approach for brain health. The findings show a statistically significant reduction in dementia risk across various subgroups, particularly among those over 60, women, and White individuals.

Showing 1 to 12 of 31 results